TCT 2015: Abbott's Bioresorbable Scaffold Matches Metal DES But Longer-Term Data Is Needed
This article was originally published in The Gray Sheet
The results of the ABSORB III trial were presented Oct. 12 at TCT. Abbott's fully bioresorbable scaffold met its endpoint, but more questions need to be answered, cardiologists say.
You may also be interested in...
The consensus among investors is that medtech has been the best-performing part of health care for the past three to four years, and investment levels remain good. Seemingly all-encompassing of late has been companies’ preoccupation with digital strategies, but there is a lot more to this unique industry than just digital.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.